Cyproheptadine
Cyproheptadine, sold under the brand name Periactin among others, is a first-generation antihistamine with additional anticholinergic, antiserotonergic, and local anesthetic properties.
Clinical data | |
---|---|
Pronunciation | /ˌsaɪproʊˈhɛptədiːn/ |
Trade names | Periactin, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682541 |
License data | |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 96 to 99% |
Metabolism | Liver, mostly CYP3A4 mediated. |
Elimination half-life | 8.6 hours |
Excretion | Faecal (2–20%; of which, 34% as unchanged drug) and renal (40%; none as unchanged drug) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.004.482 |
Chemical and physical data | |
Formula | C21H21N |
Molar mass | 287.406 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
| |
(verify) |
It was patented in 1959 and came into medical use in 1961. In 2021, it was the 280th most commonly prescribed medication in the United States, with more than 800,000 prescriptions.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.